Skip to main content

You are here:

A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)

To preliminarily evaluate the 6-month progression free survival (PFS) of combining tremelimumab and durvalumab in patients with advanced HCC (in combination with TACE).

Key Eligibility Criteria

Histologically or cytologically confirmed diagnosis of HCC OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC.

Therapeutic Area
Type of Study
Clinical trial
Study Status
Professor Peter Doran
Principal Investigator
Austin Duffy MB BCh MRCPI, Consultant Medical Oncologist